For the year ending 2025-12-31, BIIB made $9,890,600K in revenue. $1,292,900K in net income. Net profit margin of 13.07%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenues | 9,890,600 | 9,675,900 | 9,835,600 | 10,173,400 |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,404,200 | 2,310,400 | 2,533,400 | 2,278,300 |
| Research and development | 1,778,600 | 2,041,800 | 2,462,000 | 2,231,100 |
| Acquired in-process research and development, upfront and milestone expense | 471,800 | - | - | - |
| Selling, general and administrative | 2,433,600 | 2,403,700 | 2,549,700 | 2,403,600 |
| Amortization and impairment of acquired intangible assets | 515,000 | 446,700 | 240,600 | 365,900 |
| Collaboration profit (loss) sharing | - | - | - | -7,400 |
| (gain) loss on divestiture of hillerd, denmark manufacturing operations | - | - | - | 0 |
| Collaboration profit sharing/(loss reimbursement) | 290,200 | 254,400 | 218,800 | - |
| (gain) loss on fair value remeasurement of contingent consideration | -33,600 | -27,700 | 0 | 209,100 |
| Acquired in-process research and development | - | - | 0 | - |
| Impairment of rou asset | 52,900 | - | - | - |
| Restructuring charges | 48,600 | 30,200 | 218,800 | 131,100 |
| Gain on sale of priority review voucher, net | 0 | 88,600 | - | - |
| Gain on sale of building, net | - | 0 | 0 | 503,700 |
| Other (income) expense, net | -305,600 | -343,600 | -315,500 | 108,200 |
| Total cost and expense | 8,334,100 | 7,769,900 | 8,538,800 | 6,581,600 |
| Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax | - | 1,906,000 | 1,296,800 | 3,591,800 |
| Income before income tax (benefit) expense | 1,556,500 | - | - | - |
| Income tax (benefit) expense | 263,600 | 273,800 | 135,300 | 632,800 |
| Equity in (income) loss of investee, net of tax | - | 0 | 0 | 2,600 |
| Net income | 1,292,900 | 1,632,200 | 1,161,500 | 2,961,600 |
| Net income attributable to noncontrolling interests, net of tax | 0 | 0 | 400 | -85,300 |
| Net income attributable to biogen inc | 1,292,900 | 1,632,200 | 1,161,100 | 3,046,900 |
| Basic earnings per share attributable to biogen inc. (in dollars per share) | 8.83 | 11.21 | 8.02 | 20.96 |
| Diluted earnings per share attributable to biogen inc. (in dollars per share) | 8.79 | 11.18 | 7.97 | 20.87 |
| Diluted earnings per share attributable to biogen inc. (in shares) | 147,100,000 | 145,900,000 | 145,600,000 | 146,000,000 |
| Weighted-average number of common shares outstanding (in shares) | 146,500,000 | 145,600,000 | 144,700,000 | 145,300,000 |
BIOGEN INC. (BIIB)
BIOGEN INC. (BIIB)